Rich Daly

Insider profile

Currently holds positions in Catalyst Pharmaceuticals Inc, Broadridge Financial Solutions Inc and Opiant Pharmaceuticals Inc

Performance

Overall performance
2.2
Performance over holding periods
2.2
30 days 90 days 120 days
Average return 6% 8.2% 15.1%
Success rate 97% 68% 82%
Transactions
3 33% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Catalyst Pharmaceuticals Inc Feb. 19, 2015 -
Executive Chairman of the Board Broadridge Financial Solutions Inc Jan. 2, 2019 -
Independent Director Opiant Pharmaceuticals Inc June 12, 2018 -
Chief Executive Officer, Director Broadridge Financial Solutions Inc Sept. 1, 2017 - Jan. 2, 2019
Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial and Accounting Officer Palisade Bio Inc April 30, 2017 - Aug. 6, 2018
Independent Director Synergy Pharmaceuticals LLC June 30, 2015 - June 12, 2018
President, Chief Executive Officer, Director Broadridge Financial Solutions Inc Jan. 1, 2014 - Sept. 1, 2017
Chairman of the Board, President, Chief Executive Officer Palisade Bio Inc June 13, 2016 - April 30, 2017
Independent Director ADT Security Corp Jan. 9, 2014 - Jan. 1, 2017
President, Chief Executive Officer, Director Palisade Bio Inc Feb. 15, 2016 - June 13, 2016
Chief Executive Officer, Director Broadridge Financial Solutions Inc Jan. 1, 2007 - Jan. 1, 2014
Rich Daly's trades of Catalyst Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
24.63
Quantity 46,130
Value US$2,716,062
Transaction date
Proposed sale
Price
487.90
Quantity 67,008
Value US$1,198,272
Transaction date
Proposed sale
Price
15.98
Quantity 17,323
Value US$276,735
Transaction date
Purchase
Price
13.90
Quantity 1,800 New position
Value US$25,020
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-08-28 2025-08-26
S Sale
94,165 -12.9%
454.73
US$199,105 		94,165 -12.9% 454.73 US$199,105
2025-08-26 2025-08-26
PrS Proposed sale
46,130
24.63
US$2,716,062 		46,130 24.63 US$2,716,062
2025-05-30 2025-05-30
PrS Proposed sale
67,008
487.90
US$1,198,272 		67,008 487.90 US$1,198,272
2024-06-05 2024-06-04
S Sale
17,323 -6.9%
15.98
US$276,735 		17,323 -6.9% 15.98 US$276,735
2024-06-04 2024-06-04
PrS Proposed sale
17,323
15.98
US$276,735 		17,323 15.98 US$276,735
2020-03-02 2019-09-12
B Purchase
1,800 New position
13.90
US$25,020 		1,800 New position 13.90 US$25,020
2016-09-21 2016-09-19
PlS Planned sale
51,353 -16.6%
68.69
US$3,527,361 		51,353 -16.6% 68.69 US$3,527,361